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Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative 
treatment for hematologic malignancies and non-malignant diseases. Because of the 
lower toxicity of reduced intensity conditioning, the number of transplants is in constant 
increase. However, allo-HSCT is still limited by complications, such as graft-versus-host 
disease (GVHD), which is associated with important morbidity and mortality. Acute GVHD 
is an exacerbated inflammatory response that leads to the destruction of healthy host 
tissues by donor immune cells. Recently, the contribution of innate immunity in GVHD 
triggering has been investigated by several groups and resulted in the identification of 
new cellular and molecular effectors involved in GVHD pathogenesis. Interleukin-22 
(IL-22) is produced by both immune and adaptive cells and has both protective and 
inflammatory properties. Its role in GVHD processes has been investigated, and the 
data suggest that its effect depends on the timing, the target tissue, and the origin of 
the producing cells (donor/host). In this review, we discuss the role of IL-22 in allo-HSCT 
and GVHD.
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iNTRODUCTiON
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potential curative treatment 
for hematologic malignancies and non-malignant diseases. Because of the lower toxicity of reduced 
intensity conditioning, the number of transplants is in constant increase. However, allo-HSCT is 
still limited by complications, such as graft-versus-host disease (GVHD), which is associated with 
important morbidity and mortality. Acute GVHD is an exacerbated inflammatory response that 
leads to the destruction of healthy host tissues by donor immune cells. Pioneer studies from Ferrara’s 
group suggested that the acute GVHD physiopathology consists of three majors steps involving both 
innate and adaptive immune cells: (i) intestinal damage consequent to the conditioning regimen’s 
triggering of pathogen-associated molecular patterns (PAMPs) and inflammatory cytokine release, 
which activate antigen-presenting cells (APC), (ii) activation of donor alloreactive T cells, and (iii) 
proliferation, migration, and destruction of host tissues (1). Since T cells seemed crucial in the patho-
genesis process, an important number of studies focused on T cell pathways and associated cytokines. 
More recently, the contribution of innate immunity in GVHD triggering has been investigated by 
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several groups and resulted in the identification of new cellular 
and molecular effectors involved in GVHD pathogenesis (2). 
Interleukin-22 (IL-22) is produced by both innate and adaptive 
cells and has both protective and inflammatory properties. Its role 
in the GVHD process has yet to be determined, but most data 
suggest that its effect depends on the timing, the target tissue, and 
the origin of the producing cells (donor/host). In this review, we 
will discuss the new insights on IL-22 and its role in allo-HSCT 
and GVHD.
iL-22 AT A GLANCe
Interleukin-22 has been identified as IL-10-related T cell-derived 
inducible factor (IL-TIF) (3, 4). This cytokine is a member of 
the IL-10 family, together with IL-19, IL-20, IL-24, IL-26, IL-28, 
and IL-29. In humans, IL-22 is an ~20-kDa protein composed of 
146 amino acids and shares 80.8% sequence homology with the 
murine protein. The IL22 human gene is located on chromosome 
12q15, close to the IL26 and IFNγ genes (5). Although IL-10 
and IL-22 share only 22.8% sequence homology, both cytokines 
present a similar secondary structure of multiple α-helixes, 
which is specific of the IL-10 family (6). At the functional level, 
glycosylation of IL-22 seems to be more crucial for its binding to 
its receptor than for its spatial conformation (7).
Murine IL-22 production was reported for the first time in a 
lymphoma cell line after stimulation by IL-9 and also in lympho-
cytes treated with concanavalin A, independently of IL-9 (3). In 
humans, IL-22 expression was initially described in anti-CD3 or 
concavalin A-stimulated T cells (4, 8). In the immune system, it 
has been shown that only T cells, innate lymphoid cells (ILC), 
and neutrophils produce IL-22. By contrast, B cells (activated 
or not), monocytes, macrophages, dendritic cells (DC), or non-
hematopoietic cells are unable to secrete IL-22 (9–13).
Among TCR αβ-chain-expressing T cells, CD4+ T cell is the 
main source of IL-22. Initially, it was thought that only Th1 and 
Th17 produced IL-22 (10). Later, a new T cell population secret-
ing, exclusively, IL-22 has been described in humans and called 
Th22. These cells are dependent on the AHR transcription fac-
tor and express CCR10, which induces skin-homing properties 
(14, 15). To a lesser extent, IL-22 can be produced not only by 
IL-17-producing CD8+ T cells (Tc17) (16, 17) but also by a CD8+ 
population secreting exclusively IL-22 but not IL-17, called Tc22 
(18). As Th17, γδ T cells also secrete IL-22, they express the ROR-
γt transcription factor, in addition to IL-23R, CCR6, and pattern 
recognition receptors (PRR), such as TLR1, TLR2, and Dectin-1. 
In addition to IL-22, γδ T cells secrete IL-17 and IL-21, when 
stimulated with IL-23 and IL-1β, independently of TCR activation 
(19–21). Similar to what is found in Th17 cells, the transcription 
factor AHR is required for IL-22 expression but not for IL-17 in 
the latter cells. In humans, a specific subset of γδ T cells that secrete 
only IL-22 (Tγδ22) has been recently described. Its differentiation 
requires IL-1β, IL-23, and TGF-β stimulation (22).
Interleukin-22 secretion by non-T cells has been reported 
for the first time in murine models with Citrobacter rodentium 
infection (23). In this model, Rag2−/− mice, characterized by the 
lack of T cells, produced IL-22 at levels equivalent to those found 
in wild-type (WT) mice. Using immunochemistry methods, the 
authors initially attributed IL-22 secretion to CD11c expressing 
cells and speculated that DC could secrete IL-22. Nevertheless, 
in in  vitro experiments using IL-23 stimulation, myeloid cells, 
such as DC, produced a very limited amount of IL-22. These data 
indicated that secretion of IL-22 by myeloid cells seems unlikely 
(24). Interestingly, CD11c expression can be enhanced in other 
cell types and more particularly in ILCs (25). These cells repre-
sent a small fraction of the immune cells in lymphoid organs, in 
epithelial barriers, and other tissues, but they were described as 
an important source of IL-22 (25–28). Like B and T cells, ILCs 
are derived from a common lymphoid progenitor. ILCs form a 
heterogeneous group of different subsets presenting a profile of 
cytokine secretion and transcription factors similar to that of 
helper T cell subsets. Spits and Cupedo’s review notably describes 
functions and phenotypes of these populations (29). Among 
these heterogeneous populations, only group 3 ILCs produce 
IL-22. These cells are dependent on GATA-3 and ROR-γt tran-
scription factors for their development and cytokine production, 
respectively (30).
iL-22 TARGeT TiSSUeS AND CeLLS
The IL-22 receptor is a heterodimeric protein composed of 
IL-22R1 and IL-10R2 (4). Since IL-10R2 is ubiquitously expressed, 
only IL-22R1 expression conditions cellular sensitivity to IL-22. 
Expression of the latter is mainly observed not only in tissues with 
a direct interface with the external environment, such as respira-
tory mucosa (31), gastrointestinal mucosa (32, 33), and skin (13), 
but also in liver, pancreas, kidney, and thymus (8, 34–36). In these 
tissues, the responding cells include keratinocytes, dermic fibro-
blasts, intestinal and bronchial epithelial cells, intestinal subepi-
thelial myofibroblasts, hepatocytes, and acinous pancreatic cells. 
Importantly, cells from hematopoietic origin, such as monocytes, 
T and B cells, ILCs, macrophages, and DC, do not express IL-22R1 
(10) and, consequently, IL-22 cannot directly activate or inhibit 
immune cells. In addition to IL-22R1, a soluble receptor for IL-22 
called IL-22-binding protein (IL-22BP) is encoded by another 
independent gene IL22R2a (37, 38). IL-22BP is homologous to 
the extracellular chain of IL-22R1 but is only a secreted protein 
that does not result from a cleaved membrane protein. It is con-
stitutively expressed in several tissues, such as lymph nodes and 
intestine (39–41). IL-22BP is secreted by DC expressing CD103 
and CD11b in murine intestine (42, 43). In humans, IL-22BP is 
also expressed by DC and is drastically decreased in the presence 
of IL-18, or after DC maturation (42, 43). More recently, it has 
been shown that eosinophils are the most important source of 
IL-22BP in human healthy gut and contribute to an overproduc-
tion of IL-22BP in the inflamed mucosa of inflammatory bowel 
disease (IBD) patients (44).
BiOLOGiCAL FUNCTiONS: BeTweeN 
TiSSUe ReGeNeRATiON AND 
iNFLAMMATiON
Interleukin-22 signaling via its receptor induces Jak1 and Tyk2 
activation, leading to the activation of signal transducer and 
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activator of transcription (STAT) family transcription factors, 
especially STAT3 (11, 12), but also STAT1 and STAT5 (4, 8, 45, 
46). Moreover, mitogen-activated protein kinases (MAPK) 
pathways, including Erk1/2, JNK, and p38 phosphorylation, 
are also induced by IL-22 (12, 32, 47, 48). Animal models using 
IL-22-deficient mice or IL-22 neutralizing antibodies led to 
the identification of inflammatory or protective roles of IL-22. 
Interestingly, the IL-22 protective properties are associated with 
crucial biological functions of STAT3 activation in target cells 
(49). Indeed, STAT3 induces cell activation, proliferation, and 
survival via anti-apoptotic genes. Thus, IL-22 participates on 
mucosal homeostasis and epithelial barrier integrity. Murine 
models suggest that IL-22 plays a major role in intestinal regen-
eration. For instance, after mechanical wound of the colon, 
IL-22-deficient mice showed a delayed wound healing as 
compared to WT animals (46, 50). In dextran sulfate sodium 
(DSS)-induced or after CD4+CD45RBhighCD25− transfer colitis 
models, IL-22-deficient mice showed a more important loss 
of weight and a decreased survival as compared to WT mice 
(33, 51). Furthermore, in a murine model of IBD, IL-22 can 
be therapeutic. Indeed, Sugimoto’s group used an interest-
ing microinjection-based gene-delivery approach to directly 
transfer the IL22 gene into the large intestine of mice via a 
non-microbial vector and observed a decrease in inflammation, 
notably by the induction of mucins, which limit microbial flora 
and host cell interactions (33). In addition, IL-22 induces the 
secretion of several antimicrobial proteins by epithelial cells 
such as the regenerating islet-derived proteins Reg3γ and Reg3β, 
thus limiting infection by extracellular pathogens (52). IL-22 
participates in antimicrobial defense by the induction of S100 
family proteins, such as S100A7, S100A8, and S100A9, which 
sequestrate essential elements of bacteria, including iron and 
zinc. IL-22 also induces β-defensins that are able to destabilize 
bacterial membranes (11). In skin, in  vitro tests showed that 
IL-22 treatment of keratinocytes after a lesion favors cutaneous 
regeneration (53). In conclusion, IL-22 is essential for epithelial 
barrier integrity and tissue regeneration after different lesions. 
Although transgenic mice overexpressing IL-22 presented 
induction of psoriatic keratinocyte alterations and a high early 
mortality (54), IL-22 administration to healthy mice does not 
seem to induce acute or severe inflammation (11, 55). These data 
suggest the possibility of using this cytokine in human therapy 
targeting tissue regeneration.
Recently, a phase I clinical trial evaluating IL-22 safety in 
healthy volunteers has been initiated1,2 (56).
Despite its protective properties, IL-22 is also known to 
be negatively involved in several inflammatory diseases. In 
this context, the correlation between the level of IL-22 expres-
sion and the severity of the disease has been reported. In an 
endotoxemia model, IL-22 administration does not inhibit the 
pro-inflammatory cytokine production, such as TNF-α, IL-6, 
and IFN-γ, during the early phases of the disease. Moreover, in 
1 http://www.businesswire.com/news/home/20120906005611/en/Generon- 
Initiates-Phase-Clinical-Study-F-652-Australia
2 https://clinicaltrials.gov/ct2/show/NCT02406651?term=IL-22&rank=1
the late phase, IL-22-deficient mice presented a better survival, 
showing that IL-22 takes part in the systemic inflammation (57). 
This notion is also illustrated by another study showing that 
transgenic mice that artificially express IL-22 receptor on the 
surface of T cells showed a normal growth initially but presented 
a multi-organ systemic inflammation after 2 or 3 months of life 
(58). More specifically, IL-22 participates in the pathogenesis 
of rheumatoid arthritis both in humans and mice (48, 59). In 
a murine model of collagen-induced arthritis, the incidence 
of the disease is decreased in IL-22-deficient mice, associated 
with a decrease of synovial expression of IL-1β, IL-6, TNF-α, 
and MMP9 (60). Psoriasis is another disease in which IL-22 is 
clearly pathogenic and is a key mediator in its late stage, leading 
to keratinocyte lesions. Thus, a strong expression of IL-22 mRNA 
is observed in skin lesions from patients as compared to that in 
healthy skin (61). The serum level of IL-22 is also correlated with 
disease severity (12). In animal models, IL-22 blockade or IL-22 
deficiency is associated with a less severe form of experimental 
psoriasis (62). Finally, mice that artificially overexpress IL-22 
develop psoriasis-like spontaneous lesions (54). The main effects 
of IL-22 in the skin consist of keratinocyte differentiation and 
induction of pro-inflammatory effectors, such as CXCL5, IL-20, 
MMP1, and MMP3 (45, 63, 64). Overall, the effects of IL-22 seem 
to be protective or pathogenic according to the inflammatory 
context, the inflammation site, and affected tissue, as well as the 
cytokines present in the environment.
iL-22 iN THe PATHOPHYSiOLOGY OF 
GRAFT-veRSUS-HOST DiSeASe: 
iNCReASe OF iNFLAMMATORY 
ReSPONSe OR TiSSUe PROTeCTiON?
Graft-versus-host disease results from activation of donor 
T cells that recognize and destroy host tissues, such as skin and 
intestine. Given the IL-22 properties in these tissues, several 
groups assessed IL-22 contribution in acute GVHD models. We 
and others used IL-22-deficient grafts and observed that acute 
GVHD severity was decreased as compared to transplantation 
with WT grafts (65, 66). These data are in line with the critical 
role of IL-22 in systemic inflammation. Indeed, in a model where 
systemic IL-22 administration was performed via an adenovirus 
strategy, it was observed that such exposure o IL-22 induced an 
acute-phase response that could be detected in the blood and 
the liver (67). Zhao’s group showed that the main producers of 
IL-22 involved in the alloreactive immune response of GVHD 
were donor CD4+ T cells that carried CD62L− CD44high/low surface 
markers, corresponding to effector memory or recently activated 
T cells (68). Their group also demonstrated that systemic admin-
istration of IL-22 exacerbates murine GVHD, confirming the 
deleterious contribution of IL-22 to this disease (69). Similarly, 
they showed that IL-22 contributes to effector T cell expansion 
and Treg decrease. These data are in line with our observations 
showing that Treg were increased in the spleen and mesenteric 
lymph nodes of recipient mice transplanted with IL-22-deficient 
grafts (66). Several experimental reports suggest that Treg can 
limit alloreactive responses and reduce GVHD severity in mice 
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(70, 71). The expansion of Treg in the absence of IL-22 could be 
a consequence of reduced inflammation in the GVHD context, 
rather than an active mechanism.
In a chronic GVHD murine model, Okamoto’s group reported 
that more than 70% of IL-22-producing cells are CD4+ T cells. They 
treated recipient mice with an anti-IL12p40 mAb and observed 
a decrease of pathogenic Th1/Th17 cells that secrete IL-22. This 
decrease was associated with those of GVHD severity and IL-22 
levels in the serum of recipient mice (72). In human GVHD, 
the effect of IL-22 has not yet been fully established, although 
its expression seems to be increased in both acute and chronic 
GVHD. In acute GVHD, Brüggen et al. found a clear increase of 
IL-22 messenger RNA and IL-22-producing CD4+ T cells in the 
skin (73). In active chronic GVHD pediatric patients, a recent 
report demonstrated an increase of IL-22 expression in periph-
eral blood mononuclear cells as compared to that in patients with 
no GVHD (74).
One of the pathogenic mechanisms of donor-derived IL-22 
may be due to its synergy with type-I IFN that is produced during 
the allogeneic response. Recently, we showed that donor-derived 
IL-22 can synergize with type-I IFN to increase murine GVHD 
(75). At the protein level, this IL-22/type-I IFN synergy could result 
from the direct interaction between their relative receptors: the 
IFNAR physically interacts with the IFN-γ receptor and facilitates 
phosphorylated STAT1 (PSTAT1) homodimer generation (76). A 
similar interaction has also been reported between the IFNAR 
and IL-6 receptors (gp130) (77). It is not yet known whether the 
IFNAR/IL-22R interaction is physiologically relevant.
Interestingly, intracellular STAT1/STAT3 polarization can be 
controlled by IL-22 through the SOCS proteins (78). SOCS1 and 
SOCS2 are responsible for STAT1 inhibition (79). Recently, a 
report showed that SOCS1 expression was abolished in acute or 
chronic GVHD patients, suggesting that IL-22-induced STAT1 is 
no longer inhibited in this context (80). In host cells, it was shown 
that GVHD induction is associated with a rapid phosphorylation 
of STAT1 in the spleen and the liver (81). In that model, the use of 
a histone deacetylase (HDAC) inhibitor to limit murine GVHD 
led to a local and systemic decrease of STAT1 activation, together 
with a decrease of pro-inflammatory cytokine production. In 
chronic GVHD patients, STAT1 activation by type-I IFN seems 
to be critical in oral mucosal inflammation. Indeed, a higher level 
of activated STAT1 in keratinocytes has been reported in severe 
chronic GVHD patients as compared with those patients with 
no oral lesions. In this context, STAT1 activation is associated 
with an increase of Th1 inflammation mediators, such as CXCL9 
(82). These data are in line with our observation showing that 
both STAT1 and CXCL10 activation is increased in the colon of 
gastrointestinal GVHD patients (75).
Given the critical role of pro-inflammatory cytokines in 
GVHD, signal transduction inhibition seems to be a promising 
therapeutic approach. Janus kinases (Jak) are intracytoplasmic 
proteins that trigger cellular signalization leading to cytokine 
secretion through activation of STAT proteins (83). In preclini-
cal models, Jak2 and Jak3 inhibitors are efficient to limit GVHD 
(84–87). Our recent results showed that treatment with Jak 
inhibitors could also limit STAT1 activation and CXCL10 expres-
sion in intraepithelial cells (IEC).
There has been recent progress in the knowledge on the effects 
of CXCL10 family of chemokines in the inflammatory process. 
CXCL9 and CXCL10 can induce naive T cell differentiation to 
Th1 in a STAT1-dependent manner. Paradoxically, CXCL11 is 
known to bind another epitope of CXCR3 and to induce IL-10 
producing T cells (88). CXCL10 expression induced by IL-22/
type-I IFN synergy and STAT1 activation in host mucosal cells 
could participate in both Th1 recruiting and Th1-like inflamma-
tion maintenance by influencing T cell polarization. Interestingly, 
we previously showed that plasmacytoid dendritic cells (pDC) 
able to secrete IFN-α infiltrated both intestinal mucosa and 
cutaneous tissues in GVHD patients (89, 90). The relationship 
between IL-22 and pDC is suggested by data showing that IFN-α 
produced by pDC can increase the expression of IL-22R1, the 
specific subunit of IL-22R, in keratinocytes (91). Moreover, 
in humans, the differentiation of Th22, which express CCR10, 
CCR6, and CCR4 and secrete IL-22 but not IL-17, seems to be 
pDC dependent (14). Thus, IFN-α and IL-22 may participate in 
epithelial lesions at the skin or intestinal level, by an amplifying 
loop to sustain Th1 inflammation.
Despite our observations, we cannot conclude on the negative 
impact of IL-22 in allo-HSCT context. In addition to donor-
derived T cells, other cells could secrete IL-22 during allo-HSCT. 
For instance, ILCs located in the gut of host mice were shown 
to secrete large amounts of IL-22 under IL-23 stimulation and 
could resist the conditioning regimen. In the absence of GVHD 
reaction, host ILC-derived IL-22 is protective to intestinal stem 
cells (65). A high level of donor-derived ILCs in the blood of allo-
HSCT patients is associated with a less severe GVHD (92) but 
their capacity to infiltrate GVHD target tissues and their effects 
remain to be deciphered. A recent report from van den Brink’s 
group showed that IL-22 can promote ISC-mediated epithelial 
regeneration. Using ex vivo organoid culture, they demonstrated 
that group 3 ILCs secrete IL-22, which increases the growth 
of small intestinal organoids. Recombinant IL-22 treatment 
induced STAT3 activation in Lgr5+ ISC and was crucial for 
IL-22-mediated epithelial regeneration. Moreover, IL-22 treat-
ment in  vivo also enhanced the recovery of ISC and intestinal 
regeneration and reduced mortality from GVHD in transplanted 
mice (93). These observations clearly underline the essential role 
of IL-22 in damage-induced regulation and maintenance of the 
ISC compartment.
iS iL-22 A POTeNTiAL THeRAPeUTiC 
TARGeT iN GvHD?
The effect of IL-22 in allo-HSCT seems complex (Figure  1). 
Thymic RORγt+CCR6+NKp46−ILCs are crucial to secrete IL-22 
that contributes to thymic regeneration after total body irradia-
tion in mice (36). Post-transplantation IL-22 neutralization could 
have a direct impact on thymus regeneration and negatively influ-
ence immune reconstitution. The thymus regeneration seems 
more important during the first 2  weeks post-transplantation 
after IL-22 treatment, but after the second week, the size of the 
thymus is comparable to that of non-treated mice (69). However, 
a recent report showed that IL-22 administration to host mice 
FiGURe 1 | Pathogenic effect of iL-22 in GvHD. Under physiological conditions, resident ILC3 cells take part in the intestinal microbiota and mucosal infiltrating 
lymphocyte homeostasis via IL-22 secretion. In this setting, IL-22 activity is controlled by IL-22BP produced by immature DC. In the allo-SCT setting, the 
conditioning regimen leads to epithelial barrier damage and host NK cell elimination. These lesions increase DAMP and PAMP secretion and induce pDC, neutrophil, 
and antigen-presenting cell infiltration, processes which activate donor T cells through the “cytokine storm.” Thus, IL-22 and type-I IFN take part in CXCL10 
expression and induce Th1 inflammation.
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is associated with a more severe intestinal GVHD. These data 
suggest that an increase in IL-22-dependent thymus regenera-
tion is not correlated with less GVHD, but that IL-22 could be 
pathogenic for some tissues and protective for others in the same 
allogeneic context.
Paradoxically, donor-derived IL-22 aggravates intestinal 
damage during GVHD (66). It has been recently reported that 
IL-22BP expression is maximal when the intestinal barrier is pre-
served (42). Conversely, tissue lesions and bacterial translocation 
decrease IL-22BP expression. The mechanism underlying the 
expression of IL-22BP by DC is inflammasome dependent (94). 
Thus, IL-18 can inhibit IL-22BP expression by DC (95). In the 
GVHD context, the contribution of IL-18 remains controversial 
(96, 97). Nevertheless, Munoz and colleagues recently described 
an important property of this cytokine. They showed that IL-22 
maintains homeostatic IL-18 expression in epithelial cells and 
IL-8 can be augmented during infection. Moreover, active IL-18 
is responsible for a unique inflammatory feedback loop to amplify 
Th1 cell-mediated immune response (98). Whether donor-
derived IL-22 can amplify Th1 response through IL-18 secretion 
in the GVHD context remains to be addressed (Figure 2). The 
decrease of IL-22BP expression probably increases bioactive 
IL-22 at local level. These observations should be confirmed in 
allo-HSCT patients. Interestingly, antimicrobial peptides, such as 
Reg3α, that are produced by Paneth cells in response to IL-22 are 
detected in the blood of GVHD patients and have been validated 
as intestinal GVHD biomarkers (99). These data are in line with 
Eriguchi’s group observations, which showed an increase of 
defensin expression in GVHD mice, which confirm that IL-22 is 
well active in intestinal tissue during allo-HSCT (66, 100).
On the other hand, a tight relation between IL-22 and 
microbial flora has been observed. Thus, microbiota can 
directly induce IL-22 secretion by group 3 ILCs (25). Moreover, 
in epithelial tissues, IL-22 induces antimicrobial peptides, such 
as β-defensins 2 and 3, S100A8, and S100A9, which are able to 
specifically target certain microorganisms. An alteration in the 
composition of the microbiota was described in IL-22−/− mice, 
and it largely increases the susceptibility to induced colitis (101). 
This particularity should be kept in mind when IL-22−/− mice 
are used as recipients in gastrointestinal acute GVHD models. 
In addition to bacteria, the characterization of viral and fungal 
components of intestinal flora is in progress. It is probable 
that these components influence immune and also allogeneic 
responses. Recently, the role of the mycobiome has been 
addressed in different diseases (102, 103). Certain PAMPs, such 
as β-glucan or α-mannan polysaccharide chains that are part 
of the fungal membranes, can be, respectively, recognized by 
Dectin-1 and Dectin-2 receptors expressed by APC (104, 105). 
The recognition of certain patterns leads to Th17 responses 
and IL-17 and IL-22 production that control pathogens (106, 
107). Thus, IL-22 can participate to the inflammation process 
in tissues in the context of fungal infection (108). In allo-HSCT, 
FiGURe 3 | Balance between inflammatory and protective effect of 
iL-22.
FiGURe 2 | STAT1 in intestinal inflammation. In response to PAMPs and DAMPs, pDCs (green cells) infiltrate intestinal tissues and secrete type-I IFN after TLR 
activation and STAT1 phosphorylation. Type-I IFN induces STAT1 activation in intestinal epithelial cells (pink cells), leading to local CXCL10 expression. CXCL10 
induces CXCR3+ T cell (blue cells) recruitment and their differentiation into Th1, able to produce type-II IFN under STAT1 dependence. Thus, Th1 cells participate in 
local inflammation and also secrete IL-22 that contributes to STAT1 activation in IEC.
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colonization by Candida is associated with an increase in 
GVHD severity (109). Interestingly, in patients with Dectin-1 
polymorphism associated with a decreased Th17 response and 
an increase in Candida colonization, GVHD is not more severe 
(110). These data clearly suggest that the allogeneic response can 
be influenced by the mycobiome, but the relation between this 
and IL-22 and remains to be elucidated.
CONCLUDiNG ReMARKS
A solid basis of data from in vitro and in vivo models is now accu-
mulating to support IL-22s pleiotropic function. In particular, its 
dual pro-inflammatory and anti-inflammatory nature constitutes 
the largest obstacle to developing therapeutics based on this 
molecule (Figure  3). Therefore, further studies are required, 
especially in the human setting, to comprehensively explore the 
role of IL-22 in allo-HSCT.
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